Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised)
Indexado
Scopus SCOPUS_ID:84876993180
DOI 10.1186/1756-0500-6-177
Año 2013
Tipo

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background: When novel influenza viruses cause human infections, it is critical to characterize the illnesses, viruses, and immune responses to infection in order to develop diagnostics, treatments, and vaccines. The objective of the study was to collect samples from patients with suspected or confirmed A(H1N1)pdm09 infections that could be made available to the scientific community. Respiratory secretions, sera and peripheral blood mononuclear cells (PBMCs) were collected sequentially (when possible) from patients presenting with suspected or previously confirmed A(H1N1)pdm09 infections. Clinical manifestations and illness outcomes were assessed. Respiratory secretions were tested for the presence of A(H1N1)pdm09 virus by means of isolation in tissue culture and real time RT-PCR. Sera were tested for the presence and level of HAI and neutralizing antibodies against the A(H1N1)pdm09 virus. Findings and conclusions. Thirty patients with confirmed A(H1N1)pdm09 infection were enrolled at Baylor College of Medicine (BCM). Clinical manifestations of illness were consistent with typical influenza. Twenty-eight of 30 had virological confirmation of illness; all recovered fully. Most patients had serum antibody responses or high levels of antibody in convalescent samples. Virus-positive samples were sent to J. Craig Venter Institute for sequencing and sequences were deposited in GenBank. Large volumes of sera collected from 2 convalescent adults were used to standardize antibody assays; aliquots of these sera are available from the repository. Aliquots of serum, PBMCs and stool collected from BCM subjects and subjects enrolled at other study sites are available for use by the scientific community, upon request. © 2013 Keitel et al.; licensee BioMed Central Ltd.

Revista



Revista ISSN
Bmc Research Notes 1756-0500

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Sin Disciplinas
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Keitel, Wendy A. Mujer Baylor College of Medicine - Estados Unidos
2 Piedra, Pedro A. Hombre Baylor College of Medicine - Estados Unidos
3 Atmar, Robert L. Hombre
4 Demmler, Gail Mujer Baylor College of Medicine - Estados Unidos
5 El Sahly, Hana M. Mujer
6 Barrett, Jill Mujer The EMMES Corporation - Estados Unidos
7 Halpin, Rebecca A. Mujer J. Craig Venter Institute - Estados Unidos
8 Lagos, Rosanna Mujer Centro para Vacunas en Desarrollo Chile - Chile
9 Fisher-Hoch, Susan Mujer University of Texas at Brownsville and Texas Southmost College - Estados Unidos
10 Munoz, Flor M. Mujer Baylor College of Medicine - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Institutes of Health
National Institute of Allergy and Infectious Diseases
U.S. Department of Health and Human Services
University of Maryland
University of Texas
BCM Vaccine and Treatment Evaluation Unit

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
The main sample collection study has been funded with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract numbers HHSN272200800002C (BCM Vaccine and Treatment Evaluation Unit, including a subcontract to the University of Texas; Houston); HHSN27220080000 1C (subcontract to Chile from the University of Maryland). Sequencing of the viruses has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. The authors thank the members of the study team at BCM (Janet Wells and Connie Rangel) and others who contributed to the conduct of this trial, including our colleagues at the Division of Microbiology and Infectious Diseases (Linda Lambert, Katherine Muth, Shy Shorer, Andre McBride and Suzanne Murray). The authors also acknowledge technical assistance provided by Yvette Rugeley, Innocent Mbawuike, Alan Jewell, Kirtida Patel, and Sneha Thakar at BCM and Heather Hill at The EMMES Corporation.

Muestra la fuente de financiamiento declarada en la publicación.